The AJMC® Asthma compendium is a comprehensive resource for clinical news and expert insights for the chronic lung disease.
October 3rd 2024
The legacy of redlining continues to harm minority health, with Black individuals facing higher rates of health issues, linked to environmental factors and limited access to resources in regions previously redlined.
Wide Variation Found in UK Prescribing Guidance for Preferring Low-Carbon Asthma Inhalers
September 1st 2022Understanding if local prescription patterns are influenced by guidance could help policymakers understand what is needed to further encourage a shift to asthma inhalers with less of a climate impact.
Read More
Deepwater Horizon Oil Spill Led to 60% Higher Risk of Later Asthma for Cleanup Workers
August 28th 2022Workers involved in cleaning up the 2010 Deepwater Horizon disaster, the country’s largest oil spill, were 60% more likely to be diagnosed with asthma or experience asthma symptoms 1 to 3 years afterwards, compared with those who were not involved in the cleanup.
Read More
Worse Vascular Outcomes Found in Patients With Asthma
August 14th 2022Patients with symptoms of asthma, regardless of physiological confirmation, experienced worse vascular outcomes and greater cardiovascular risk, which may be due to short-acting beta agonist (SABA) use, according to the results of a recent study.
Read More
Obesity, Physical Inactivity Linked With Higher Risk for Activity Limits in Asthma
August 5th 2022Patients with asthma and all types of obesity, or with all types of obesity and physical inactivity, have an increased risk for limited activity of daily living, according to the results of a recent study.
Read More
Social Determinants of Health Associated With Asthma Morbidity in Children
July 25th 2022At-risk rates of asthma morbidity in children varied across census tracts in Washington, DC, and were significantly correlated with social determinants of health in each area, according to a recent study.
Read More
Dupilumab Safe, Effective Among Patients With Comorbid Asthma, CRSwNP
July 11th 2022Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
Dupilumab Demonstrates Safety, Efficacy Across Several Type 2 Inflammatory Diseases
July 2nd 2022Research presented at the European Academy of Allergy and Clinical Immunology Annual Congress show the safety and efficacy of dupilumab across several progressive diseases with underlying type 2 inflammation, including eosinophilic esophagitis (EoE), severe asthma, and severe chronic rhinosinusitis with nasal polyps.
Read More
Clinical and Economic Burden of Uncontrolled Severe Noneosinophilic Asthma
Among patients with severe asthma with low eosinophils untreated with biologics, there is a high burden of disease among those who have suboptimal disease control.
Read More
Caregivers of Children With Asthma Lack Knowledge About Disease Management
June 22nd 2022About 70% of caregivers studied reported that they preferred to use the emergency department for treatment for asthma exacerbations, indicating current education is insufficient for managing asthma at home.
Read More
Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count
June 8th 2022Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
Read More
Dupilumab Reduces OCS Dosage, Improves Lung Function for Asthma, CRSwNP
May 22nd 2022Dupilumab was associated with reductions in exacerbations and oral corticosteroids (OCS) dosage, as well as improved lung function, in patients with OCS-dependent asthma with and without comorbid chronic rhinosinusitis with nasal polyps.
Read More
Biologics Provide Opportunity to Manage Moderate to Severe Pediatric Asthma, Improve QOL
May 13th 2022Pediatric patients with asthma and their caregivers are faced with significant health and cost burdens, and biologics provide an opportunity to improve quality of life and asthma control, according to a panel of experts.
Read More
Improved Sense of Smell Achieved With Biologics for CRS With Nasal Polyps, Asthma
May 12th 2022Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and severe asthma reported significant improvement in their sense of smell when treated with the biologics omalizumab, mepolizumab, reslizumab, or benralizumab, with no significant differences observed between the treatment groups.
Read More
Clinical Improvement of AERD Achieved With Dupilumab Use for Asthma, CRS With Nasal Polyps
May 3rd 2022Patients with aspirin-exacerbated respiratory disease (AERD) who initiated treatment with dupilumab as an add-on asthma or chronic rhinosinusitis with nasal polyps therapy reported rapid clinical improvement that was sustained after 3 months.
Read More